TRIM21 and torsades de pointes: The patients in the whole TdP cohort showed a high prevalence of recognized acquired QT-prolonging risk factors, on average five per patient, including those “conventional”, mainly organic heart diseases (85%), QT-prolonging medications (76%), and electrolyte imbalances (75%), and “non-conventional”, such as systemic inflammation (83%) and anti-Ro/SSA autoantibodies (55%).